Sanofi (NASDAQ:SNY) Shares Sold by Trust Investment Advisors

Trust Investment Advisors trimmed its position in shares of Sanofi (NASDAQ:SNY) by 5.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,698 shares of the company’s stock after selling 1,502 shares during the quarter. Trust Investment Advisors’ holdings in Sanofi were worth $1,278,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Rise Advisors LLC lifted its holdings in Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after acquiring an additional 251 shares during the period. SRS Capital Advisors Inc. lifted its stake in shares of Sanofi by 289.1% in the first quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock valued at $25,000 after purchasing an additional 344 shares during the period. Householder Group Estate & Retirement Specialist LLC acquired a new stake in shares of Sanofi in the third quarter valued at about $26,000. Fairfield Bush & CO. purchased a new stake in Sanofi during the first quarter worth about $26,000. Finally, Salem Investment Counselors Inc. acquired a new position in Sanofi during the fourth quarter worth about $27,000. 10.04% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SNY shares. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Morgan Stanley initiated coverage on Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 target price on the stock. Finally, TheStreet cut Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $55.00.

Sanofi Price Performance

SNY stock traded down $0.72 on Thursday, reaching $45.39. The company had a trading volume of 4,359,459 shares, compared to its average volume of 1,897,695. The company’s fifty day moving average is $47.55 and its 200 day moving average is $48.69. The company has a market cap of $114.82 billion, a P/E ratio of 19.25, a PEG ratio of 1.71 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. Sanofi has a 1 year low of $42.63 and a 1 year high of $57.82.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). The company had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a net margin of 12.56% and a return on equity of 27.47%. On average, research analysts forecast that Sanofi will post 4.16 earnings per share for the current year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a $1.478 dividend. This represents a yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio is 58.47%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.